In PAH, there is a reduction in antiproliferative BMP signalling, while activin A levels are increased, with activin binding to ActRIIA triggering proliferative signalling in vascular cells and promoting occlusive remodelling in the pulmonary vascular bed [71,72,73,74]. Here, ACVR2A is linked to pulmonary arterial hypertension.